Effects of morphine-3-glucuronide on the antinociceptive activity of peptide and nonpeptide opioid receptor agonists in mice.

Abstract

The effects of morphine-3-glucuronide (M3G), a metabolite of morphine, were determined on the antinociceptive actions, as measured by the tail flick test, of morphine, a mu-opioid receptor agonist, of U-50,488H, a kappa-opioid receptor agonist of [D-Pen2, D-Pen3]enkephalin (DPDPE), a delta 1-opioid receptor agonist, and of [D-Ala2,Glu4]deltorphin II (deltorphin II), a delta 2-opioid receptor agonist in mice. Morphine administered ICV (2.5 micrograms/ mouse) or SC (10 mg/kg), U-50,488H (25 mg/kg, IP), DPDPE (15 micrograms/mouse; ICV), and deltorphin II (15 micrograms/mouse, ICV) produced antinociception in mice. Intraperitoneal or ICV injections of M3G did not produce any effect on the tail flick latency nor did it affect the antinociception-induced by morphine, U-50,488H, DPDPE, or deltorphin II. Previously M3G has been shown to antagonize the antinociceptive effects of morphine in the rat. It is concluded that in the mouse, M3G neither produces hyperalgesia nor modifies the actions of mu-, kappa-, delta 1-, or delta 2-opioid receptor agonists.